Insulet Stock

Insulet EBITDA per Employee

The EBITDA per Employee of Insulet (PODD) as of Sep 15, 2026 is 87,740.74 USD. In the previous year, EBITDA per Employee was 57,203.70 USD — a change of 53.38% (higher).

EBITDA per Employee

87,740.74USD

YoY

53.38%

Last updated:

EBITDA per Employee of Insulet is 2026 87,740.74 USD. EBITDA per Employee of Insulet was 2025 57,203.70 USD. It decreases by 53.38% higher compared to the previous year.

The Insulet EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2018
5,078.33 USD
Jan 1, 2019
9,259.26 USD
Jan 1, 2020
10,148.15 USD
Jan 1, 2021
15,129.63 USD
Jan 1, 2022
6,759.26 USD
Jan 1, 2023
40,740.74 USD
Jan 1, 2024
57,203.70 USD
Jan 1, 2025
87,740.74 USD
The Insulet EBITDA per Employee history
YEAREBITDA per EmployeeYoY
87,740.74USD+53.38%
57,203.70USD+40.41%
40,740.74USD+502.74%
6,759.26USD-55.32%
15,129.63USD+49.09%
10,148.15USD+9.60%
9,259.26USD+82.33%
5,078.33USD-471.23%
-1,367.96USD-40.57%
-2,301.85USD-74.50%
-9,025.19USD+296.32%
-2,277.22USD
Access this data via the Eulerpool API

Insulet Stock analysis

What does Insulet do? Insulet Corp is an American company that was founded in 2000 and is headquartered in Acton, Massachusetts. Its goal is to improve the quality of life for people with diabetes by developing innovative products that make living with this chronic disease easier. Insulet Corp is known for its product "OmniPod." The OmniPod is a wireless, portable disposable insulin pump system that offers an alternative option to traditional pumping and insulin delivery systems. The OmniPod system consists of two small devices: a pod worn on the skin and a PDM (Personal Diabetes Manager) that regulates insulin delivery. The pod contains an insulin reservoir that communicates wirelessly with the PDM. The insulin dose is administered directly into the body without needles or tubes. Insulet Corp is also introducing the "OmniPod DASH System." This new system combines the proven design of the OmniPod pod with a new color touchscreen handheld device that allows for even easier operation. The DASH system also offers the ability to control insulin dosing from a smartphone, which can be taken with diabetics wherever they go. The success of the OmniPod system has made Insulet Corp a leading company in the diabetes industry. The company has also developed and introduced products and services in other areas of diabetes treatment. Insulet Corp has developed another product called "Amigo." This product is a personalized travel and training program for people who require insulin. Amigo offers specialized and personalized training to support diabetics in managing complex situations. It also offers diet and exercise plans to make living with diabetes easier. Insulet Corp has also developed a software called "OmniPod Horizon." This software is a closed-loop system that automatically adjusts insulin dosing to keep blood sugar levels within the target range. The system is currently in the development phase and is expected to be released in 2020. Insulet Corp has also developed a program called the "OmniPod Partner Program," which targets doctors and pharmacists. The program provides training and educational materials for healthcare providers to help them better treat and manage their patients. Since 2009, Insulet Corp has been listed on the NASDAQ stock exchange and has continuously evolved since then. The company currently has over 1500 employees and operates in North America, Europe, and the Middle East. Insulet Corp is a company focused on the development of innovative, life-changing products and services. It is expected to continue to play a significant role in improving the quality of life for people with diabetes in the future. Insulet is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Insulet stock

EBITDA per Employee of Insulet is 87,740.74 USD in 2026.

EBITDA per Employee of Insulet changed from 57,203.70 USD to 87,740.74 USD, representing a 53.38% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Insulet since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Insulet historically and in real time.

Access this data via the Eulerpool API

Workforce — Insulet

All Key Metrics — Insulet